GeoVax Announces $6 Million Public Offering to Advance Immunotherapy and Vaccine Development

GeoVax Labs, Inc., a clinical-stage biotechnology company, has announced a public offering aiming to raise approximately $6 million. This financial move is designed to support the company's ongoing research and development in immunotherapies and vaccines targeting cancer and infectious diseases. The offering involves the sale of about 9.2 million units, each consisting of one share of common stock and warrants, priced at $0.65 per unit.

The warrants included in the offering allow for the purchase of up to approximately 18.5 million shares of common stock, with an exercise price of $0.65 per share. These warrants are immediately exercisable upon issuance and remain valid for five years. Roth Capital Partners is serving as the exclusive placement agent for this offering.

GeoVax intends to allocate the net proceeds from this offering towards working capital and general corporate purposes, furthering its mission to develop groundbreaking medical solutions. The offering is expected to close around July 2, 2025, pending the fulfillment of standard closing conditions.

This strategic financial initiative underscores GeoVax's commitment to advancing its clinical programs, including its next-generation COVID-19 vaccine and innovative oncology treatments. The company's efforts are particularly focused on addressing unmet medical needs in immunocompromised populations and enhancing the efficacy of existing vaccines.

For more details on the offering, interested parties can refer to the SEC's website at http://www.sec.gov.